Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Count me in: using a patient portal to minimize implicit bias in clinical research recruitment.

Kannan V, Wilkinson KE, Varghese M, Lynch-Medick S, Willett DL, Bosler TA, Chu L, Gates SI, Holbein MEB, Willett MM, Reimold SC, Toto RD.

J Am Med Inform Assoc. 2019 May 13. pii: ocz038. doi: 10.1093/jamia/ocz038. [Epub ahead of print]

PMID:
31081898
2.

Low serum magnesium is associated with faster decline in kidney function: the Dallas Heart Study experience.

Ferrè S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, Toto RD, Moe OW, Neyra JA.

J Investig Med. 2019 Mar 2. pii: jim-2018-000966. doi: 10.1136/jim-2018-000966. [Epub ahead of print]

PMID:
30826804
3.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
4.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
5.

Impact of Acute Kidney Injury and CKD on Adverse Outcomes in Critically Ill Septic Patients.

Neyra JA, Mescia F, Li X, Adams-Huet B, Yessayan L, Yee J, Toto RD, Moe OW.

Kidney Int Rep. 2018 Jul 29;3(6):1344-1353. doi: 10.1016/j.ekir.2018.07.016. eCollection 2018 Nov.

6.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

PMID:
30418475
7.

2018 American Society of Consultant Pharmacists Annual Meeting & Exhibition.

Bridgeman M, Prete D, Rolston N, Abazia D, Sturgill M, Finn L, Summers D, Marvanova M, Henkel P, Thompson J, Dewey M, Friesner D, Marvanova M, Alessi C, Cuellar L, Yamagishi L, O'Neil C, Erickson O, Mazzei K, Kamal K, Early N, Bainter B, Hanson L, Schmitz E, Loomis A, Norberto M, Hume A, Meyer M, Batra R, Likar D, Enguidanos S, Liu C, Kotansky B, Fisher A, Ruby CM, Pruskowski J, Karim SNA, Yong BSW, Alessi C, Cuellar L, Slattum P, Crouse E, Delafuente J, Donohoe K, Ogbonna K, Peron E, Powers K, Price E, Zimmerman K, Rahim S, Gendron T, Slattum P, Donohoe K, Cho C, Zimmerman K, Crouse E, Peron E, Powers K, Price E, Slattum P, Donohoe K, Elliott L, Minter C, Morin M, Marshall L, Stevens G, Cordaro C, Hill M, Nagy K, Kroustos KR, Sobota KF, Mahan R, Bailey T, Ioannou K, Mansour D, Thompson T, Chatellier K, Schwenk A, Ruby C, Chen TS, Li S, James M, Spilios M, Leschak A, Levine A, Forgette S, Oluigbo N, Szollosi D, Avalime D, Weaver SB, Maneno M, Ettienne E, Yi JY, Hart L, Gray S, Ozalas S, Miller K, Dave R, Bork J, Emmelhainz J, Adams K, Postolski J, Willoughby M, Feldman E, Braham K, Miller C, Barbagallo D, Seabury R, Noviasky J, Alessi C, Cuellar L, Dabhi J, Bartlett D, Le T, Simoni-Wastila L, Kuzucan A, Simoni-Wastila L, Le T, Park S, Simoni-Wastila L, Le T, Park S, Choi M, Simoni-Wastila L, Park S, Le T, Choi M, Simoni-Wastila L, Khokhar B, Choi M, Le T, Simoni-Wastila L, Brody P, Hejna M, Mason J, Graham M, Micceri J, Lypska R, Quinn B, Wilson H, Wahler R, Aloyo M, Tomm V, Hill A, Obringer A, Butterfoss K, Blak J, Balcer R, Boza J, Foster A, Shafique E, Kleven C, Wigle P, Brown B, Alessi C, Cuellar L, Meyer K, Mobley-Bukstein W, Singh H, Perez E, Mira AE, Kuehner W, Czechowski L, Cook H, Brandt N, Parson J, Fornaro R, Brandt N, Claeys K, Zarowitz B, Mansour D, McFadden C, Simpkins S, Ojowa F, Klutts A, Holmes S, Smith E, Cornman JR, Doran K, Resnick B, Brandt N, Umeozulu C, Williams A, Brandt N, Hennawi G, Thomas D, Gerber DK, Meyer K, Sharma K, Cooke C, Howard A, Chater R, Vogler A, Brandt N, Kennett-Hayes K, Elliott L, Engelbert J, Hargrave E, Bambico C, Patel K, Warriner C, Slattum P, Desai NR, Rowan CG, Alvarez P, Fogli J, Toto RD, Desai NR, Alvarez P, Fogli J, Reed P, Owens MK, Greden JF, Rothschild AJ, Zandy S, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechairo B, Parikh S, Donohue J, Feldman G, Sethi S, Barnes C, Pendyala S, Bourdet D, Ferguson G, Barnes C, Pendyala S, Crater G, Fogli J, Mayo M, Gross C, Miyawa J, Ono R, Woods S, Garza D, Panov N, Fogli J, Moran E, Sabesan V, Wertman J, Ngim K.

Consult Pharm. 2017 Oct 1;33(10):572-608.

PMID:
30322434
8.

Defining Hypertension: Role of New Trials and Guidelines.

Toto RD.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1578-1580. doi: 10.2215/CJN.05350418. Epub 2018 Sep 21. No abstract available.

PMID:
30242028
9.

Effects of sodium glucose co-transporter 2 inhibitors on the kidney.

de Albuquerque Rocha N, Neeland IJ, McCullough PA, Toto RD, McGuire DK.

Diab Vasc Dis Res. 2018 Sep;15(5):375-386. doi: 10.1177/1479164118783756. Epub 2018 Jul 2. Review.

PMID:
29963920
10.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

11.

Bardoxolone-the Phoenix?

Toto RD.

J Am Soc Nephrol. 2018 Feb;29(2):360-361. doi: 10.1681/ASN.2017121317. Epub 2018 Jan 25. No abstract available.

12.

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.

Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P.

Am J Nephrol. 2017;46(6):488-497. doi: 10.1159/000485326. Epub 2017 Dec 14.

13.

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.

Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, Toto RD, Trivedi MH.

JAMA. 2017 Nov 21;318(19):1876-1890. doi: 10.1001/jama.2017.17131.

14.

Association of serum magnesium with all-cause mortality in patients with and without chronic kidney disease in the Dallas Heart Study.

Ferrè S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, Toto RD, Moe OW, Neyra JA.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1389-1396. doi: 10.1093/ndt/gfx275.

15.

SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?

Toto RD.

Nephron. 2017;137(1):64-67. doi: 10.1159/000450895. Epub 2017 Jul 26. Review.

16.

Serum Potassium and Cardiovascular Outcomes: The Highs and the Lows.

Toto RD.

Clin J Am Soc Nephrol. 2017 Feb 7;12(2):220-221. doi: 10.2215/CJN.00030117. Epub 2017 Jan 31. No abstract available.

17.

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2016 Dec;68(6):873-881. doi: 10.1053/j.ajkd.2016.07.022. Epub 2016 Sep 16.

18.

Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.

Srivastava A, Adams-Huet B, Vega GL, Toto RD.

J Investig Med. 2016 Aug;64(6):1102-8. doi: 10.1136/jim-2016-000102. Epub 2016 Jul 7.

19.

Cumulative Fluid Balance and Mortality in Septic Patients With or Without Acute Kidney Injury and Chronic Kidney Disease.

Neyra JA, Li X, Canepa-Escaro F, Adams-Huet B, Toto RD, Yee J, Hedayati SS; Acute Kidney Injury in Critical Illness Study Group.

Crit Care Med. 2016 Oct;44(10):1891-900. doi: 10.1097/CCM.0000000000001835.

20.

APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.

Freedman BI, Gadegbeku CA, Bryan RN, Palmer ND, Hicks PJ, Ma L, Rocco MV, Smith SC, Xu J, Whitlow CT, Wagner BC, Langefeld CD, Hawfield AT, Bates JT, Lerner AJ, Raj DS, Sadaghiani MS, Toto RD, Wright JT Jr, Bowden DW, Williamson JD, Sink KM, Maldjian JA, Pajewski NM, Divers J.

Kidney Int. 2016 Aug;90(2):440-449. doi: 10.1016/j.kint.2016.04.027. Epub 2016 Jun 22.

21.

Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.

Jain N, Li X, Adams-Huet B, Sarode R, Toto RD, Banerjee S, Hedayati SS.

Am J Cardiol. 2016 Feb 15;117(4):656-663. doi: 10.1016/j.amjcard.2015.11.029. Epub 2015 Dec 7.

22.

Transplantation: The role of RAAS blockade in kidney transplantation.

Toto RD.

Nat Rev Nephrol. 2016 Mar;12(3):129-31. doi: 10.1038/nrneph.2015.201. Epub 2015 Dec 14. No abstract available.

23.

Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT.

Chertow GM, Beddhu S, Lewis JB, Toto RD, Cheung AK.

J Am Soc Nephrol. 2016 Jan;27(1):40-3. doi: 10.1681/ASN.2015101125. Epub 2015 Nov 9.

24.

Dipstick albuminuria and acute kidney injury recovery in critically ill septic patients.

Neyra JA, Li X, Yessayan L, Adams-Huet B, Yee J, Toto RD; Acute Kidney Injury in Critical Illness Study Group.

Nephrology (Carlton). 2016 Jun;21(6):512-8. doi: 10.1111/nep.12637.

PMID:
26421662
25.

From Phosphaturia to Cardiovascular Protection: Is Fibroblast Growth Factor-23 the Heart of the Matter?

Toto RD.

Circulation. 2015 Jul 7;132(1):7-9. doi: 10.1161/CIRCULATIONAHA.115.017177. Epub 2015 Jun 9. No abstract available.

26.

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD.

Am J Kidney Dis. 2015 Sep;66(3):429-40. doi: 10.1053/j.ajkd.2015.02.324. Epub 2015 Apr 29.

27.

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD.

Clin J Am Soc Nephrol. 2014 Feb;9(2):295-301. doi: 10.2215/CJN.07460713. Epub 2014 Jan 9.

28.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.

N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

29.

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.

Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D.

Nephrol Dial Transplant. 2013 Nov;28(11):2841-50. doi: 10.1093/ndt/gft445.

PMID:
24169612
30.

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM.

Am J Nephrol. 2013;37(3):212-22. doi: 10.1159/000346948. Epub 2013 Feb 28.

31.

The pathogenesis and management of hypertension in diabetic kidney disease.

Van Buren PN, Toto RD.

Med Clin North Am. 2013 Jan;97(1):31-51. doi: 10.1016/j.mcna.2012.10.003. Epub 2012 Nov 27. Review.

PMID:
23290728
32.

Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).

Jain N, Trivedi MH, Rush AJ, Carmody T, Kurian B, Toto RD, Sarode R, Hedayati SS.

Contemp Clin Trials. 2013 Jan;34(1):136-44. doi: 10.1016/j.cct.2012.10.004. Epub 2012 Oct 22.

33.

The prevalence of persistent intradialytic hypertension in a hemodialysis population with extended follow-up.

Van Buren PN, Kim C, Toto RD, Inrig JK.

Int J Artif Organs. 2012 Dec;35(12):1031-8. doi: 10.5301/ijao.5000126.

PMID:
23065874
34.

RAS blockade, hyperkalemia and AKI--look and you will find.

Toto RD.

Nat Rev Nephrol. 2012 May;8(5):257-8. doi: 10.1038/nrneph.2012.62.

PMID:
22473512
35.

Longitudinal progression trajectory of GFR among patients with CKD.

Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright JT Jr, Greene TH.

Am J Kidney Dis. 2012 Apr;59(4):504-12. doi: 10.1053/j.ajkd.2011.12.009. Epub 2012 Jan 26.

36.

A method for isolation and identification of urinary biomarkers in patients with diabetic nephropathy.

Fisher WG, Lucas JE, Mehdi UF, Qunibi DW, Garner HR, Rosenblatt KP, Toto RD.

Proteomics Clin Appl. 2011 Dec;5(11-12):603-12. doi: 10.1002/prca.201000156.

37.

Intradialytic hypertension and its association with endothelial cell dysfunction.

Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto RD.

Clin J Am Soc Nephrol. 2011 Aug;6(8):2016-24. doi: 10.2215/CJN.11351210. Epub 2011 Jul 14.

38.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators.

N Engl J Med. 2011 Jul 28;365(4):327-36. doi: 10.1056/NEJMoa1105351. Epub 2011 Jun 24.

39.

Differential outcomes between dialysis modalities: purely a reflection of selection bias?

Inrig JK, Toto RD.

J Am Soc Nephrol. 2011 Jun;22(6):989-90. doi: 10.1681/ASN.2011040394. No abstract available.

40.

Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.

Van Buren PN, Adams-Huet B, Toto RD.

J Investig Med. 2010 Dec;58(8):950-6. doi: 10.231/JIM.0b013e3181ff46a5.

41.

Intensive blood-pressure control in hypertensive chronic kidney disease.

Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group.

N Engl J Med. 2010 Sep 2;363(10):918-29. doi: 10.1056/NEJMoa0910975.

42.

Debate: PRO Position. People with chronic kidney disease should have a blood pressure lower than 130/80 mm Hg.

Toto RD.

Am J Nephrol. 2010;32(4):370-3; discussion 379-80. doi: 10.1159/000319636. Epub 2010 Sep 3. No abstract available.

43.

Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort.

Toto RD, Greene T, Hebert LA, Hiremath L, Lea JP, Lewis JB, Pogue V, Sika M, Wang X; AASK Collaborative Research Group.

Am J Kidney Dis. 2010 Nov;56(5):896-906. doi: 10.1053/j.ajkd.2010.05.016.

44.

Aldosterone blockade in chronic kidney disease: can it improve outcome?

Toto RD.

Curr Opin Nephrol Hypertens. 2010 Sep;19(5):444-9. doi: 10.1097/MNH.0b013e32833ce6d5. Review.

45.

Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death.

Hedayati SS, Minhajuddin AT, Afshar M, Toto RD, Trivedi MH, Rush AJ.

JAMA. 2010 May 19;303(19):1946-53. doi: 10.1001/jama.2010.619.

46.

Screening and evaluation of study subjects in patient-oriented research.

Toto RD.

J Investig Med. 2010 Apr;58(4):608-11. doi: 10.231/JIM.0b013e3181c9f68c.

PMID:
20009952
47.

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD.

J Am Soc Nephrol. 2009 Dec;20(12):2641-50. doi: 10.1681/ASN.2009070737. Epub 2009 Nov 19.

48.

Is choice of antihypertensive agent important in improving cardiovascular outcomes in high-risk hypertensive patients?

Inrig JK, Toto RD.

Am J Kidney Dis. 2009 Dec;54(6):1000-4. doi: 10.1053/j.ajkd.2009.08.003. Epub 2009 Sep 25. No abstract available.

49.

Decreased pulse pressure during hemodialysis is associated with improved 6-month outcomes.

Inrig JK, Patel UD, Toto RD, Reddan DN, Himmelfarb J, Lindsay RM, Stivelman J, Winchester JF, Szczech LA.

Kidney Int. 2009 Nov;76(10):1098-107. doi: 10.1038/ki.2009.340. Epub 2009 Sep 2.

50.

Supplemental Content

Support Center